本文關(guān)鍵詞：西酞普蘭治療肺癌術(shù)后抑郁癥的臨床觀察　出處：《中國(guó)藥房》2016年17期 　論文類型：期刊論文

  更多相關(guān)文章： 西酞普蘭 抑郁癥 安全性 肺癌

【摘要】：目的:觀察西酞普蘭治療肺癌術(shù)后抑郁癥的臨床療效及安全性。方法:選取肺癌術(shù)后伴發(fā)抑郁癥的患者114例,按隨機(jī)數(shù)字表法分為觀察組和對(duì)照組,各57例。對(duì)照組患者術(shù)后給予營(yíng)養(yǎng)支持、平衡電解質(zhì)等常規(guī)治療,未服用抗抑郁藥物;觀察組患者術(shù)后口服氫溴酸西酞普蘭片20 mg,qd。兩組患者均連續(xù)治療6周。觀察兩組患者臨床療效及治療前后漢密爾頓抑郁量表(HAMD)評(píng)分、漢密爾頓焦慮量表(HAMA)評(píng)分、健康調(diào)查量表(SF-36)評(píng)分,并記錄不良反應(yīng)發(fā)生情況。結(jié)果:觀察組總有效率為87.72%,顯著高于對(duì)照組的71.93%,差異有統(tǒng)計(jì)學(xué)意義(P0.05);兩組患者治療前HAMD評(píng)分、HAMA評(píng)分及SF-36各項(xiàng)評(píng)分和總分比較,差異無統(tǒng)計(jì)學(xué)意義(P0.05);兩組患者治療后HAMA評(píng)分、HAMD評(píng)分顯著降低,且觀察組顯著低于對(duì)照組,SF-36各項(xiàng)評(píng)分和總分顯著升高,且觀察組顯著高于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者均未見明顯不良反應(yīng)發(fā)生。結(jié)論:西酞普蘭治療肺癌術(shù)后抑郁癥的療效顯著,能明顯改善患者精神狀態(tài)和生存質(zhì)量,且安全性較好。
[Abstract]:Objective: To observe the clinical efficacy and safety of citalopram in the treatment of lung cancer postoperative depression. Methods: 114 cases of patients with lung cancer postoperative depression, were randomly divided into observation group and control group, 57 cases each. The patients in the control group were given nutritional support, electrolyte balance and other conventional treatment. Not taking antidepressant drugs; the patients in the observation group after oral administration of Citalopram Hydrobromide Tablets 20 mg, qd. two groups of patients were treated for 6 weeks. Observe two groups of patients before and after treatment of the Hamilton Depression Scale (HAMD) score, Hamilton Anxiety Scale (HAMA) score, health survey scale (SF-36) score, and record the occurrence of adverse reactions. Results: the total effective rate of observation group was 87.72%, significantly higher than 71.93% in the control group, the difference was statistically significant (P0.05); the HAMD scores of two groups of patients, HAMA score and SF-36 score and total score difference. With no significant difference (P0.05); the two groups of patients after treatment HAMA score, HAMD score decreased significantly, and the observation group was significantly lower than the control group, the SF-36 score and total score were significantly increased, and the observation group was significantly higher than the control group, the differences were statistically significant (P0.05). Two groups of patients had no obvious adverse reactions. Conclusion: the efficacy of citalopram in the treatment of lung cancer postoperative depression significantly, can significantly improve the quality of life and mental state of the patients with good safety.

【作者單位】： 河北大學(xué)附屬醫(yī)院胸外科;河北省精神衛(wèi)生中心情感障礙科;
【分類號(hào)】：R734.2;R749.4
【正文快照】： 肺癌是臨床常見的惡性腫瘤之一。流行病學(xué)調(diào)查研究顯示,肺癌發(fā)病率、死亡率呈逐年上升趨勢(shì),且治療方法仍無突破性進(jìn)展,肺癌已成為當(dāng)今世界死亡率最高的惡性腫瘤[1-2]。目前,以手術(shù)為主的綜合療法是其最主要的治療手段,但術(shù)后不少患者出現(xiàn)不同程度的抑郁,嚴(yán)重影響了患者的生存

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張曉東;鮑曉麗;;艾司西酞普蘭治療持續(xù)的軀體形式疼痛障礙對(duì)照研究[J];中國(guó)社區(qū)醫(yī)師(醫(yī)學(xué)專業(yè));2012年06期

2 王潤(rùn)梅;馬金萍;李俊福;施萬平;;艾司西酞普蘭對(duì)肝功能的影響[J];山西醫(yī)藥雜志(下半月刊);2012年06期

3 蘇寶蘭;;過量服用利培酮及西酞普蘭1例[J];臨床精神醫(yī)學(xué)雜志;2012年04期

4 劉曉靜;張艷;李翠鸞;王e，

本文編號(hào)：1402827